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Within the neurovascular unit (NVU), the blood–brain barrier (BBB) operates as a key
cerebrovascular interface, dynamically insulating the brain parenchyma from peripheral
blood and compartments. Increased BBB permeability is clinically relevant for at least
two reasons: it actively participates to the etiology of central nervous system (CNS)
diseases, and it enables the diagnosis of neurological disorders based on the detection
of CNS molecules in peripheral body fluids. In pathological conditions, a suite of glial,
neuronal, and pericyte biomarkers can exit the brain reaching the peripheral blood and,
after a process of filtration, may also appear in saliva or urine according to varying
temporal trajectories. Here, we specifically examine the evidence in favor of or against
the use of protein biomarkers of NVU damage and BBB permeability in traumatic head
injury, including sport (sub)concussive impacts, seizure disorders, and neurodegenerative
processes such as Alzheimer’s disease. We further extend this analysis by focusing on
the correlates of human extreme physiology applied to the NVU and its biomarkers. To
this end, we report NVU changes after prolonged exercise, freediving, and gravitational
stress, focusing on the presence of peripheral biomarkers in these conditions. The
development of a biomarker toolkit will enable minimally invasive routines for the
assessment of brain health in a broad spectrum of clinical, emergency, and sport settings.
Keywords: neurovascular unit, blood biomarkers, saliva, concussion, epilepsy, neurodegeneration, traumatic brain
injury, extreme sports
INTRODUCTION: FROM BLOOD–BRAIN BARRIER TO
BLOOD–BRAIN DYNAMIC INTERFACE
The blood–brain barrier (BBB) is the complex and finely tuned network of brain capillaries
governing the homeostatic exchange of ions, molecules, and cells between the brain and the
peripheral blood (1–3). The importance of the BBB in the understanding and diagnosis of
neurological disorders and brain health is recognized (4). The notion of BBB has evolved from
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that of a static brain shield to that of a dynamic blood–brain
interface where endothelial cells continuously communicate with
mural cells (pericytes and smooth muscle) and glia (astrocytes
and microglia), located near neurons and spatially assembled
to constitute the neurovascular unit (NVU) (Figure 1) (2). A
precise layering of cells and extracellular matrixes forms an
impermeable wall (Figure 1B). BBB dysfunction has etiologic
and diagnostic significance (4), and BBB permeability is a key
element of perivascular and neuroinflammation (Figure 1B1)
(5, 6). Increased BBB permeability provokes an immediate loss
of homeostatic control of ions, ATP, and neurotransmitters
levels in the brain, promoting abnormal synaptic transmission
or neuronal firing, possibly leading to neurological sequelae (6–
13). On the other hand, neuronal activity significantly influences
cerebrovascular functions in health and disease conditions (14,
15). Diagnostically and because of increased BBB permeability,
peripherally injected imaging contrast agents can access the
brain parenchyma while a suite of central nervous system (CNS)
FIGURE 1 | The dynamic NVU multicellular layout. (A) Within the NVU, the BBB encapsulates a set of unique properties of the microvascular capillary and
post-capillary venules. The BBB endothelium lacks fenestrations, is assembled by structured tight junctions (TJs), and expresses luminal or abluminal transporters,
altogether finely regulating brain homeostasis for proper neuronal physiology. These endothelial specializations are generated and controlled by precise interactions
with pericytes, astrocyte end-feet, and microglial cells, all participating to the NVU. (B) Exploded view to illustrate the varying cellular composition and wall thickness of
the intima, media, and adventitia layers. The endothelial basement membrane (BM) embeds pericytes. A second basement membrane is deposited by astrocytes and
surrounds the end-feet. At the capillary level, the endothelial and parenchymal basement membranes merge. At the post-capillary venules, the two basement
membranes separate to provide a perivascular space that allows for immune cells homing. (B1) Commonly reported pathological modifications leading to BBB
permeability or NVU damage. (C) The cerebrovasculature in numbers (A, arteries; V, veins; CTX, cortex; SMC, smooth muscles cells). Proper BBB commences as the
deepening cortical arteries (diameter > 100µm in mice) branch into arterioles (diameter 15–50µm; wall thickness 5–10µm) and capillaries (diameter < 10µm; wall
thickness a few µm). Pial vessels have glia limitans and an anatomically distinguishable Virchow-Robin space (B). Blood flow velocity rates in cortical mouse arterioles
and capillaries are 3 and <0.5 mm/s, respectively. Capillary blood flow decreases with cortical depth (down to 0.1 mm/s). Diameter ranges (rodent) and anatomical
abundance of glia, Virchow-Robin space, collagens, and mural cells (smooth muscles or pericytes) is provided. The multicellular layering within the tunica media (sign
+++ indicates more than three smooth muscle cells at the arteries; + indicates one layer of pericytes at the BBB) is the major determinant of vascular thickness and
elasticity. Original images by NM and IGF graphical service.
proteins (see Table 1) or nucleic acids [circulating free DNA
and microRNA; for a review see (44, 45)] can exit into the
peripheral blood (Figures 2A–C, 3A–C). Contrast MRI and
CT scans are common clinical tools, while monitoring the
levels of CNS proteins in peripheral body fluids represents a
novel strategy for identifying BBB and neuronal damage (46).
Importantly, the NVU connects with specialized brain acellular
spaces through which the cerebrospinal and interstitial fluids
carry ions, molecules, and proteins across the parenchyma or
toward waste clearance pathways (Figure 2B) (47–50). This
spatial perivascular and interstitial connectivity is important in
the context of contrast-based brain imaging, possibly influencing
the availability of biomarkers and their exit trajectories from the
CNS [Figure 2; see (46, 51, 52) for a review]. Starting from these
fundamental concepts, we here examine the evidence supporting
the development and the use of specific peripheral biomarker
proteins to detect glioneuronal damage and BBB permeability in
a plethora of clinical, emergency and sport-related settings.
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TABLE 1 | Peripheral biomarker proteins of glio-neuronal damage and BBB permeability.
Proteins MW
(kDa)
Role as
biomarker
Estimated
half-life in blood
Usage temporal
trajectories
Source Sampling
methods
CNS disease Reported (and varying)
blood baselines
References
GFAP 50 Astrocyte damage
or astrogliosis
48 h (16) Acute and
Subacute
(hours–days) (17)
Astrocyte
cytoskeleton
No clearly reported
extra-cranial
sources (18)
Venipuncture
CSF
TBI
Multiple sclerosis
AD
Baseline 0.01 ng/ml
TBI with negative CT
0.21 ng/ml
TBI with positive
CT 0.73 ng/ml
(17–21)
S100B 11 BBB and astrocyte
damage,
astrogliosis
2–6 h (22) Acute (min, hours)
(17)
Astrocyte calcium
binding protein
CNS development
Extra-cranial
sources
[adipocytes (18)]
Venipuncture
CSF
Urine
Saliva
TBI
Epilepsy
Multiple sclerosis
Pediatric 0.11 ng/ml (23)
Adults 0.045 ng/ml (24)
(sub)concussion, mTBI:
0.1 ng/ml (25, 26)
(17, 23, 25, 27–29)
UCH-L1 24 Neuronal cell
damage (30)
7–9 h (31) Acute (min, hours)
Subacute (days)
(17)
Axonal integrity
Extra-cranial
sources
[neuromuscular
junction (18)]
Venipuncture
CSF
TBI
Neurodegeneration
Pediatric 0.09 ng/ml (19)
TBI with negative CT:
0.14 ng/ml
TBI with positive CT:
0.44 ng/ml
TBI with negative CT 261
pg/ml (21)
(19, 21)
NSE 47 Neuronal cell
damage
30 h (32) Acute (min, hours)
Subacute (days)
(17)
Neuron
cytoplasmic
enolase
Detected in blood
erythrocytes
Venipuncture
CSF
TBI
Epilepsy
Adults 6.1µg/ml (24) (33, 34)
NFL 68 Axonal injury,
neuronal death
3 weeks (35) Subacute days to
weeks (17) and
chronic
Neuron class IV
intermediate
filaments
of cytoskeleton
Venipuncture
CSF
TBI
Neurodegeneration
Multiple sclerosis
Threshold CSF
386 ng/ml (36)
(37, 38)
PDGFRβ 123 Pericyte reactivity
or damage
na Subacute (39) Pericytes–
endothelial interface
CSF Neurodegeneration See (40) for graphic baseline
(115 % increase in CSF
between no and mild
cognitive impairment)
(39)
Tau,
pTau
50–80 Neuronal or axonal
damages,
neurodegeneration
10 h (41) S majuscle,
subacute, and
chronic (17)
Neuronal
microtubule-
associated
proteins
Aggregates into
neurofibrillary tangles
Venipuncture
CSF
Neurodegeneration
AD
Blood total and
phosphorylated tau, (42)
T-tau control = 65.59 fg/ml
P-tau control = 20.85 fg/ml
P-tau/T-tau ratio control =
30.94
Total-tau in serum 4.4 pg/ml
(24)
Threshold CSF
P-tau 78 pg/ml (39)
(17, 24, 43)
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PERIPHERAL BIOMARKERS: BASIC
CONCEPTS AND FOCUS ON TRAUMATIC
BRAIN INJURY
Elevated BBB permeability, or dysfunction, occurs in response to
an acute injury (e.g., head trauma, stroke, and status epilepticus)
and may be present throughout CNS disease progression
(e.g., neurodegeneration, epileptogenesis, andmultiple sclerosis),
often due to inflammation (5–7, 13). Peripheral biological
fluids represent suitable matrices to detect and quantify brain-
derived proteins reporting BBB permeability and susceptibility
to glio-neuronal damage (27–29, 53). Table 1 provides a list
of protein biomarkers and their characteristics, properties, and
proposed use in diagnostics. In general, peripheral biomarker
proteins must (i) be present in brain interstitial fluids or be
released by neurovascular cells into the interstitial or perivascular
spaces, reaching the peripheral blood across a leaky BBB or by
cerebrospinal fluid (CSF)–blood exchange (Figures 2A, 3A,B);
(ii) have a concentration gradient driving passive diffusion
[Figure 2C; see (29)]; (iii) have a known and appropriate half-
life to allow diagnostic interpretation (29) (biomarker half-life in
peripheral fluids may impact usefulness in acute vs. long-term
settings; see Table 1); and (iv) have a low molecular weight to
allow a rapid egress across the damaged barriers or interfaces
(19, 25, 27).
The bulk of neurological clinical biomarker literature has
often focused on traumatic brain injury (TBI), with a recent
emphasis on mild TBI (mTBI) (18, 54). Within this framework,
the astrocytic protein S100B (55) has been examined as a
peripheral biomarker of BBB permeability and gliosis (Table 1
and Figures 3A,B). Early proof-of-principle studies showed
serum S100B levels to rapidly increase in response to a sudden
BBB permeability, supporting the hypothesis that perivascular
S100B can readily exit the brain (27, 28, 56). S100B was reported
to rule out mTBI sequelae in emergency room settings (57), and
measurement of blood S100B levels displayed a 99.7% negative
predictive value (NPV) (57–60). Further evidence indicated that
monitoring S100B after a mTBI could override the need for a CT
scan for the identification of intracranial injury, with an excellent
NPV (61). However, another study reported no relationship
between serum S100B concentration and mTBI severity (62). In
sports, S100B blood levels increased immediately after football
games as compared to pregame baselines in players experiencing
repeated head hits (25, 63). The evidence of a rapid S100B surge
in blood after sub concussive hits was confirmed in follow-up
studies (63–65). Importantly, extra-CNS sources of S100B were
reported, representing a potential confounding factor if timing
of blood draws in relation to injury is not adequately controlled
and standardized (18, 66). These concerns have been discussed
in (23, 67, 68).
The astrocytic glial fibrillary actin protein (GFAP) and the
neuronal ubiquitin carboxyl-terminal hydrolase isoenzyme L1
(UCH-L1) are important biomarker candidates for glioneuronal
damage (Table 1 and Figures 3A,B). UCH-L1 is also expressed
at the neuromuscular junction (69, 70) while the contribution of
extracranial sources of GFAP is debated (20, 71, 72). Monitoring
FIGURE 2 | In and out the brain: plausible biomarker exit routes and transport.
(A) NVU cell disassembly causes disruption of brain homeostasis, allowing
blood (red asterisks and arrow) and brain (green asterisks and arrow)
components directly crossing the permeable BBB (TJ, tight junctions; A,
astrocytes; P, pericytes; N, neurons). (B) Brain fluid paths regulate the
movement of molecules (e.g., biomarkers) within the brain parenchyma into
the blood and the CSF: (a) the CSF is produced by subarachnoid arteries and
(b) the choroid plexus (blood-to-CSF barrier). By bulk flow mechanisms, the
CSF diffuses at the cortical levels and in periventricular organs, constituting a
possible vehicle for biomarker transport. (c) BBB damage allows biomarkers
exiting (or entering) the brain. (d,e) Parenchymal bulk flow and CSF
reabsorption occurs at larger veins, dural venous sinuses, and dural lymphatic
vessels, sites where biomarkers could accumulate. (C) Concentration
gradients (green/red 1 or arrows) between the peripheral blood and the brain
parenchyma are the underpinning for pathological modifications and the
driving force for biomarkers (e.g., MR contrast agent brain entry, red; protein
biomarkers brain exit, green). Original images by NM.
of blood GFAP and UCH-L1 levels was used to grade brain injury
after TBI. GFAP and UCH-L1 levels were increased in non-
concussive and concussive head trauma as compared to body
trauma (73, 74). The analysis of blood GFAP (or S100B) levels
within 24 h from the head injury was proposed as a means to
improve the detection of TBI and to identify patients in need
of a subsequent MRI, in addition to routine CT surveillance
(75, 76). GFAP and UCH-L1 blood levels were used to rule out
intracranial injuries and the need for CT scans, showing high
test sensitivity and NPV (21). One study reported no significant
difference in blood UCH-L1 between control and players who
sustained repetitive head hits (77). Collectively, this evidence
points to GFAP as a diagnostic candidate to be used in TBI
(33, 54, 71, 72). In two studies (78, 79), however, GFAP and
UCH-L1 levels were below the lower limits of quantification or
detection (LLOQ or LLOD, respectively) in a percentage of both
TBI and trauma control groups, representing a possible concern
for estimating NPV (20, 80).
Important biomarkers detecting neuronal damage are myelin
basic protein (MBP), neuron-specific enolase (NSE), tau, and
neurofilament light chain [NfL; Table 1 and Figures 3A,B; see
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FIGURE 3 | Peripheral biomarkers of BBB permeability and brain damage. (A) Under physiological conditions, BBB tightness within a healthy NVU limits proteins from
exiting the brain into the peripheral blood. (B) In conditions of brain damage, each neurovascular cell acts as a source of specific biomarker(s) (color coded), accessing
the peripheral blood across a leaky BBB. The production or secretion of biomarkers at each NVU cell type depends on the severity, time, and the progression of
disease states (see Table 1). (C) Integrating the use of brain imaging and peripheral biomarkers is a developing strategy to detect brain damage and to validate the
usefulness of specific biomarker proteins in peripheral fluids. Original images by NM, JB, and IGF graphical service.
(43)]. Blood MBP levels were unchanged in a pediatric mTBI
population as compared to controls. Interestingly, MBP levels
remained elevated for up to 2 weeks in case of intracranial
hemorrhage (81). NfLs are found in axons and have been
proposed as biomarkers of axonal damage triggered by mTBI, for
example, after an amateur boxing bout (82–84). S100B levels were
also increased following amateur boxing (85). Further evidence
indicated neurofilament heavy chain increase after mTBI (82).
Finally, NSE levels in CSF were shown to be proportional to
TBI severity, in the setting of moderate or severe TBI (86–88).
NSE in the blood is less investigated due to its presence in
erythrocytes (89, 90). Collectively, these data support the further
development of blood biomarker toolkits of TBI, with a special
relevance tomild head injury and sport-related (sub)concussions,
when emergency and sideline diagnostic solutions need to be
readily accessible.
PHOSPHORYLATED TAU AS AN
EMERGING BLOOD BIOMARKER OF
ALZHEIMER’S AND
NEURODEGENERATIVE DISEASES
Accumulating evidence points to blood phosphorylated tau
as a promising biomarker to improve the diagnosis and
staging of and to enable trials in Alzheimer’s disease (AD)
subjects. In a cross-sectional study performed in AD patients,
phosphorylated tau isoforms were used as diagnostic biomarkers
to track disease progression (91). A method measuring attomolar
concentrations of tau isoforms in plasma was implemented
using stable isotope labeling kinetics and mass spectroscopy.
Changes in plasma p-tau, particularly p-tau217, mirrored specific
changes in CSF to detect phosphorylation of soluble tau
and amyloidosis. No correlation was found between CSF and
plasma p-tau202 levels. Plasma p-tau217 level distinguished
amyloid-negative from amyloid-positive groups regardless of
the cognitive status, indicating that p-tau217 in plasma may
be an accurate biomarker of abnormal brain tau metabolism.
Furthermore, a longitudinal study of familial AD (presenting
pathogenic mutations in PSEN1 or APP genes) included 19
symptomatic and 51 asymptomatic participants where plasma p-
tau181 levels were quantified by using a single-molecule array
(Simoa) method (92). Elevated plasma p-tau181 concentrations
segregated symptomatic mutation carriers from non-carriers.
In another cross-sectional study including the Arizona-based
neuropathology cohort (37 AD and 47 without AD), the Swedish
BioFINDER 2 cohort [121 AD, 178 mild cognitive impairment
[MCI], 301 without AD, and 99 other neurological disorders],
and a Columbian autosomal-dominant AD kindred (365 PSEN1
E280A mutation carriers and 257 mutation non-carriers),
plasma tau phosphorylated at the threonine 217 (p-tau217)
was quantified by the Meso Scale Discovery (MSD) assay as a
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diagnostic AD biomarker (93). Among 1,402 participants from
the three cohorts, plasma p-tau217 discriminated AD from
other neurological disorders with higher accuracy compared with
plasma p-tau181, plasma Nfl, CSF p-tau181, and CSF Aβ42:Aβ40
ratio. A positive correlation between CSF and plasma p-tau217
was found in the Swedish BioFINDER 2 cohort. Finally, a high-
sensitivity immunoassay measuring p-tau181 in plasma and
serum was developed (94). A positive correlation was reported
between plasma and CSF p-tau181 levels, distinguishing Aβ-
negative cognitively unimpaired older adults from Aβ-positive
older adults and Aβ-positive individuals with MCI.
Furthermore, at the BBB, the low-density receptor-related
protein 1 (LRP1) plays an important role in regulating
cerebrovascular permeability (95). sLRP1, a truncated soluble
form of LRP1, freely circulates in plasma, and it sequesters
unbound Aβ in the peripheral circulation (96). Plasma sLRP1
levels are significantly reduced in AD patients, and sLRP1
binding to Aβ is disrupted by oxidation (96, 97). Impaired
sLRP1-mediated binding of plasma Aβ was suggested as an
early biomarker for MCI preceding AD-type dementia (97). In
summary, this evidence supports the further development of tau-
based blood biomarkers as an accessible test for the screening and
diagnosis of AD within the spectrum of cognitive impairments
and dementia.
PERIPHERAL BIOMARKERS OF BBB
PERMEABILITY AND SEIZURE
CONDITIONS
The use of blood biomarkers extends to epilepsies, a cluster
of diseases where BBB damage represents an etiological or a
contributing pathophysiological player (98–100). A first study
(67) demonstrated that blood S100B is elevated at seizure onset
and after seizures, in support of the hypothesis that BBB damage
may trigger a seizure (7, 101–103). A systematic review analyzed
18 studies and a total of 1,057 subjects, indicating that epileptic
patients displayed elevated S100B blood levels as compared to
controls (104). Meta-regression analyses showed that gender
and mean age can impact serum S100B levels (104). Another
study correlated MRI T1 peri-ictal imaging to blood S100B in
drug-resistant epileptic patients, confirming the increase in BBB
permeability during a seizure (105). Increased S100B blood levels
were reported in pediatric temporal lobe epilepsy, with blood
samples obtained 30min after a complex partial seizure (106).
Children suffering from intractable focal epilepsy displayed
elevated blood S100B levels as compared to controls (107).
One study included 39 patients suffering from simple febrile
seizures and age- and sex-matched controls, showing no S100B
differences between groups when assessed immediately after
seizures (108). These findings were corroborated in a follow-
up study, (109) with the conclusion that febrile seizures
are relatively harmless to the developing brain. Currently,
a clinical trial is investigating whether S100B, as well as
other protein biomarkers, increase in blood after a first
generalized seizure could be used to predict first-to-chronic
seizure conversion in adult subjects (https://clinicaltrials.gov/ct2/
show/NCT02424123). Moreover, NSE elevations were reported
in blood over time in patients affected by temporal lobe and
extratemporal lobe epilepsies (110). Finally, recent evidence
indicates miRNA in blood, or body fluids, as potential
biomarkers indicating neurovascular and neuroinflammatory
modifications occurring in specific forms of epilepsies [see (111–
113) for comprehensive topic reviews]. In summary, blood
biomarkers could represent a surrogate method of clinical
electroencephalographic explorations to examine damage and
brain neurophysiology in epileptic patients.
IMAGING BBB PERMEABILITY AND BRAIN
DAMAGE: IS THE INTEGRATION WITH
BLOOD BIOMARKERS POSSIBLE?
Available evidence supports the prospective use of blood
biomarkers to detect NVU damage in acute and chronic
neurological conditions. In this context, can peripheral
biomarkers replace brain imaging? This is an important
question especially if one considers the logistics (scarce imaging
availability in rural areas and emergency, sport, and combat
settings) and economic advantages that come with peripheral
biomarkers, notwithstanding the complications associated with
radiation exposure (e.g., CT scan). As a result, the diagnostic
equivalence of blood biomarkers and enhanced MRI or CT
scans (114–119) is being investigated. Accumulating evidence
has shown that mTBI represents an optimal clinical arena to
study the usefulness of imaging and peripheral biomarkers,
also fulfilling an urgent clinical need (120–122). Neuroimaging
techniques [CT scan (61)] show limitations for the diagnosis of
mTBI patients (122, 123). Importantly, blood levels of GFAP,
tau, and NfL were higher in patients with TBI-related findings
on CT as compared to subjects presenting with normal CT,
where the only significant predictor of damage was GFAP (124).
Combining the biomarkers tau, NfL, and GFAP showed a good
discriminatory power for detecting MRI abnormalities, even
in mTBI patients with a normal CT (124). Furthermore, peak
serum S100B levels negatively correlated with resting-state
brain connectivity and behavioral outcomes in mTBI to severe
TBI cases (125). S100B has proven its high NPV to rule out
intracranial bleeding in patients after mTBI. However, its
specificity for brain parenchyma structural lesions remains
debated, and MRI is required for a specific explanation of clinical
symptoms (76, 126, 127). Positron emission tomography (PET)
and radiolabeled biomarkers were tested along with blood
biomarkers. The [18F]AV1451 (flortaucipir) tau ligand was
detected at the white/gray matter junction in frontal, parietal,
and temporal brain regions, a typical localization of chronic
traumatic encephalopathy (CTE) and tauopathy in veterans.
Elevated levels of Nfl were also reported in plasma (43). Finally,
TBI is associated with inflammation as blood levels of IL6, TNFα,
and VEGF were increased in CT- and MRI-positive patients as
compared to controls (126).
Importantly, newer brain imaging approaches are being
tested. Proton magnetic resonance spectroscopy (1H-MRS)
represents an emerging neuroimaging modality to track the
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metabolic changes occurring after TBI (128, 129). Spectroscopy
can predict changes of key metabolites such N-acetylaspartate
(NAA), a marker of neuronal loss (130), and its early decrease
associates with long-term poor outcomes in clinical pediatric
mTBI and moderate TBI (130). Experimentally, spectroscopy
modifications post injury were linked to altered astrocyte
metabolism (131). Brain structural changes observed using
diffusion tensor imaging were correlated to astrocyte dysfunction
and astrogliosis at early (1–7 days) and late (60 days) time points
after injury (132, 133). Tractography provides an opportunity
for measuring structural alterations in the white matter that are
not detected by conventional structural MRI (134). Magnetic
encephalography has also been proposed to study mTBI damage,
in addition to being used for post-traumatic stress disorders (135,
136). Collectively, these data underscore the need for integrating
the temporal and quantitative profiles of emerging imaging read-
outs with the dynamics of peripheral biomarker of NVU damage.
These studies will allow us to fully understand whether blood
biomarkers can reliably act as surrogates for brain imaging.
SALIVA AS A BIOMARKER MATRIX:
GENERAL CONCEPTS
Another key cellular “barrier” can be exploited for diagnostic
purposes, namely, the salivary glands and gingival vessels,
both interfacing with the peripheral blood (Figures 4A,B) (53,
137–144). While plasma and serum are considered as classic
biofluids for assessment of systemic biomarkers, saliva is being
increasingly viewed as a matrix with a high diagnostic value (141,
145). Saliva collection is economical, safe and can be performed
without the assistance of specialized health care personnel,
allowing for point-of-injury (POI) sampling. Saliva lacks cellular
and soluble components (e.g., coagulation cascade). As the
leakage of brain-derived biomarkers in saliva undergoes a process
of biological filtration (53, 137, 146), the use of saliva does not
require separation steps that are an obstacle to the development
of POI blood tests (138, 139). Human saliva is a clear,
slightly acidic (pH 6.0–7.0) heterogeneous biofluid composed of
water (99%), proteins (0.3%), and inorganic substances (0.2%)
(147). Saliva contains enzymes, hormones, antibodies, nucleic
acids, antimicrobial constituents, and cytokines (148), which
accumulate in salivary glands and are secreted into the oral cavity
through acinar cell ducts (149). Available protocols indicate that
saliva samples can be stored short term at room temperature
and long term at −20◦C or −80◦C without significant protein
degradation, similar to serum or plasma samples (150, 151).
Relevant information inherent to the preparation and the
technical handling of saliva samples can be found in (150, 152–
154).
The whole saliva (WS) proteome, when compared with
the plasma proteome, displays a larger proportion (14.5%) of
low-molecular-weight proteins (<20 kDa), in contrast to only
7% for the plasma proteome (154). The highest fraction of
proteins found in WS ranges from 20 to 40 kDa, whereas the
40–60 kDa range is the largest fraction for plasma. This is
consistent with selective permeability between blood and saliva
FIGURE 4 | The blood-to-saliva interface and proposed salivary biomarkers.
(A) Schematic representation of molecular transport or passage from blood
into salivary glands. Salivary glands are highly vascularized, enabling exchange
of blood-based constituents (ions, proteins, etc.). Alterations in the molecular
composition of the blood may lead to modifications of the composition of
saliva. (B) Biomarker extravasation from brain to blood depends on the
permeability of the BBB to a given biomarker. Under normal conditions and
when the BBB is intact, endothelial tight junctions restrict the passage of polar
or large (> ∼300 Da) molecules. When the BBB is breached, appearance in
the blood of brain-derived protein biomarkers occur. Next, the passage of
protein from blood to saliva is proposed. (C) Possible protein ratio of saliva to
blood for biomarkers and pro-inflammatory factors (see text for details and
references). Original images by DJ and CH.
for low-molecular-weight proteins. Five diagnostic alphabets are
outlined in saliva, including proteome (153, 155), transcriptome
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(156, 157), microRNA (158), metabolome (159), andmicrobiome
(160). Saliva is used by clinical laboratories for the detection of
secretory IgA antibodies, for the analysis of salivary cortisol and
hormones, and for genetic purposes (161–163).
SALIVARY BIOMARKERS OF NVU
DAMAGE: A NEW DIAGNOSTIC
OPPORTUNITY?
The salivary proteome has been characterized in CNS disease
conditions, such as schizophrenia, bipolar disorders, and genetic
disorders including Down’s syndrome and Wilson disease (164).
An overview of biomarkers identified in saliva for the diagnosis
of neurodegenerative diseases such as AD, Parkinson’s disease,
amyotrophic lateral sclerosis, and multiple sclerosis is provided
in (165). Inflammatory biomarkers (e.g., IL-1β, TNF-α, and IL-6)
have been quantified in saliva (166).
The deployment of POI salivary tests represents an
opportunity for the detection of time-sensitive brain injuries
(139–141, 167, 168). NSE was shown as a possible diagnostic
salivary biomarker for neuronal damage in patients post stroke
(169). Saliva samples have been analyzed for S100B levels,
pro-inflammatory factors, and microRNAs in the settings of
TBI (168, 170, 171). In particular, S100B levels in saliva were
elevated in children post TBI (171). In another pilot study,
15 adult patients with suspected TBI and 15 control subjects
were studied. Average salivary S100B level was 3.9-fold higher
than blood S100B level, regardless of the presence of pathology
[S100B]saliva correlated positively with [S100B]serum, and salivary
S100B levels were as effective in differentiating TBI patients from
control subjects as serum levels (172).
In an attempt to further accentuate the diagnostic significance
of salivary testing, we reviewed the literature to obtain potential
blood-to-saliva ratios for a number of proteins (Figure 4C). This
search was directed to proteins that are not secreted by salivary
glands. These proteins can access the salivary fluid by pericellular
capillary leak, primarily the crevicular fluid. Importantly, it is
currently unknown whether the steady-state permeability of the
blood-to-saliva protein diffusion is preserved even at times when
the BBB is breached due to brain insults. Literature references
were used to examine insulin (173, 174), EGF (175), HGH (19,
176), S100B (18, 54–56, 177–180), adiponectin (181), prostate-
specific antigen (PSA) (182), and cytokines (183). To our
knowledge, there are no reports of salivary BDNF or NFL levels.
All retrieved values were plotted to outline the theoretical cutoff
properties of salivary filtration (Figure 4C). Large molecules
(e.g., IgG) can be present in saliva owing to active secretion or
local production.
Finally, we examined whether blood-to-saliva biomarkers’
passage could be empirically predicted or modeled (153).
Available data indicate that saliva is not a diluted substitute
for the determination of plasma protein levels, as indicated by
the incoherent plasma and saliva proteomes (152). Therefore,
understanding the kinetic protein passage from blood to saliva
is difficult. In the past, a model describing the passage of
biomarkers from the brain into the peripheral blood was
proposed (27–29). A physiologically based pharmacokinetic
model can be used to describe the distribution of drugs and small
molecules in body fluids (184). This computational approach
can estimate the extent and time course of salivary biomarkers
originating from the brain, offering the likelihood of a protein
in saliva to be blood-borne (185). The physiologically based
pharmacokinetic model used to describe the distribution of
brain-derived biomarkers in blood was expanded to include an
idealized salivary gland receiving its vascular supply from the
external carotid. The venous output was mimicked according
to the properties of jugular vein branches. To approximate
the combined contribution of transcellular and paracellular
pathways of protein extravasation across capillary endothelial
cells and salivary gland epithelia, the following equation was used
to calculate Js, the transfer of protein from blood to saliva:
Js = Jv∗(1− R)∗Cp+ (Cp− Ci)∗PS (1)
where Js (mol/min) is the mass transfer from blood to saliva,
Jv (ml/min) is the blood flow to the salivary gland, R is the
reflectance of the vascular wall, Cp (mol/L) is the concentration
of biomarker in the serum, Ci (mol/L) is the concentration
of biomarker in the saliva, and P and S refer to permeability
(cm/s) and surface of exchange (cm2), respectively. The value
of reflectance has no dimension and has a range from one (no
passage of protein) to 0 (protein passage dictated by diffusion
alone). The value of reflectance is derived from pore radius and
molecular radius. To estimate PS, we used PS = Jv ∗ Ci/(Cp –
Ci) with salivary flow at 1 ml/min and Ci and Cp at 2.5 and 61.5
mg/ml, respectively. These values were derived by measurements
and transfer of albumin levels from blood and saliva. The
equation can be greatly simplified by fitting experimental data
to confirm their accuracy. Once this is done, the predictors of
passage of a given protein are primarily related to its molecular
size (vascular wall reflectance) and the presence of a gradient
for passage from blood to crevicular fluid. For (1), note that
if the reflectance tends toward 1 (large molecular weight), the
first term equals zero, thus leaving only the permeability of the
capillary wall and the osmotic gradient as variables. Considering
that permeability also depends on molecular size, a cutoff for
extravasation seems to be mostly related to the size of the
permeating protein. By using other computational models, it was
shown that the physicochemical properties of proteins were the
main predictors of presence in saliva. Among several properties,
molecular size was the most relevant (185, 186).
It is important to underscore that the use of saliva samples
comes with confounding factors. For instance, gingivitis
or periodontal disease can affect the identification and
quantification of proteins. It has been shown that submandibular
saliva flow rates are lower in AD patients as compared to
controls (187), possibly impacting the proportion of proteins
detectable (188). In summary, fully defining the qualitative
and quantitative characteristics of salivary biomarkers in
physiological and neuropathological conditions is important to
develop non-invasive point of care applicable to NVU screening.
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PUSHING THE BBB LIMITS: RELEVANCE
OF PERIPHERAL BLOOD BIOMARKERS IN
HUMAN MODELS OF EXTREME BRAIN
PHYSIOLOGY
Here, we focus on extreme sport settings that can be exploited
as ‘human’ models to study BBB permeability, neuronal damage,
and hemodynamic modifications in a controlled spatiotemporal
manner. We review the evidence supporting the use of blood
biomarkers to detect neurovascular modifications associated
with extremes of cerebral blood flow (Figure 5A). These
models share similar pathophysiological features unified by
the cerebral formation of free radicals, associated reactive
oxygen/nitrogen species (ROS/RNS), and impaired cerebral
autoregulation (CA).
EXERCISE, CEREBROVASCULAR
REGULATION, AND BLOOD BIOMARKERS
Evidence indicates that moderate-intensity continuous training
(MICT) and corresponding improvements in cardiorespiratory
fitness (CRF) can increase cerebral perfusion and vasoreactivity
across the human life span (192, 193), translating into a lower
risk of stroke mortality and dementia (194, 195). The primary
mechanisms include accelerated neurogenesis, in particular
of the hippocampal dentate gyrus (196); reduction in β-
amyloid (197); neuro-oxidative inflammatory nitrosative stress
(198); proprioceptive adaptations incurred by movements that
require sustained mental effort (199); increased brain-derived
neurotrophic factor that modulates brain plasticity by promoting
neuritic outgrowth and synaptic function (200); and improved
BBB integrity and bolstering of tight junctions (201). More
recently, high-intensity interval training (HIIT) has emerged
as a more time-efficient model of exercise that can potentially
promote superior improvements in CRF and cerebrovascular
adaptation (191). However, this type of exercise characterized
by high-flow/high-arterial-pressure transmission poses unique
challenges for the brain with emerging evidence suggesting that
an acute bout of HIIT could increase BBB permeability in the
absence of neuronal injury (e.g., increased blood S100B and no
NSE changes), subsequent to a free radical-mediated impairment
in dynamic CA that persists into the recovery period (202)
(Figure 5B).
HIGH-ALTITUDE MOUNTAINEERING,
FREEDIVING, NVU DYNAMICS, AND
BLOOD BIOMARKERS
High-altitude (HA) mountaineering (Figure 6A) and freediving
(Figure 6B) represent unique physiological models to study
severe arterial hypoxemia (O2 lack) and hypocapnia/hypercapnia
(CO2 lack/excess) in ‘extreme’ athletes who consistently operate
at, or very close to, the limits of human consciousness
(189, 212). Diffusion-weighted magnetic resonance imaging
has identified increases in brain volume, T2 relaxation time
(T2-rt), and apparent diffusion coefficients (ADCs) in healthy
participants acutely exposed to hypoxia, taken to reflect
extracellular vasogenic edematous brain swelling (205, 206).
These changes were pronounced in the splenium and genu of
the corpus callosum, the likely consequence of a unique vascular
constitution. Densely packed horizontal fibers characterized by
short arterioles that lack adrenergic tone likely render it more
susceptible to hyperperfusion edema in the setting of hypoxic
cerebral vasodilatation and/or autoregulatory impairment (205,
206). Local sampling of CSF and arterial–jugular venous blood
concentration gradients of biomarkers including S100B indicated
that BBB disruption is likely minor and linked to increased free
radical formation (207, 216).
Some mountaineers, notably those who ascend (too) rapidly
to altitudes above 2,500m and thus not adequately acclimatized,
can develop acute mountain sickness (AMS), a primary disorder
of the CNS characterized by headache that is associated with,
if not the primary trigger for, other vegetative symptoms
(217). Traditionally, AMS has been considered a mild form
of HA cerebral edema (HACE, the most malignant of all
HA illnesses, oftentimes proving fatal) with a common
pathophysiology of intracranial hypertension subsequent to
vasogenic edematous brain swelling at opposing ends of
a clinical continuum. An increase in intracranial pressure
(ICP) could potentially result in the mechanical stimulation
of pain-sensitive unmyelinated fibers that reside within the
trigeminal–vascular system, triggering the symptoms of a
headache (218). This makes intuitive sense in light of an
early study that identified an increased T2 signal in the
white matter of mountaineers with moderate to severe AMS
in whom clinical HACE had not yet developed (no ataxia
or altered consciousness) (219). However, follow-up MRI
studies consistently failed to support this concept, with no
clear relationships observed between hypoxia-induced increases
in brain volume or T2-rt and cerebral AMS scores (206,
220). Indeed, the only defining morphological feature that
distinguishes the AMS brain from its healthy counterpart
is a selective attenuation in the ADC signal taken to
reflect intracellular (cytotoxic) edema that likely coexists
with extracellular vasogenic edema (206, 220). Attenuation
of the ADC signal likely reflects fluid redistribution from
within the extracellular space, as intracellular (astrocytic)
swelling proceeds without any additional increment in brain
volume, edema, or ICP (221). The underlying causes and
temporal sequence are unknown, perhaps a reflection of
ion pump suppression subsequent to (free radical-mediated)
downregulation of Na+/K+-ATPase activity (211). More recent
evidence suggests that a functional impairment in cerebral
‘venous outflow’ at the level of the transverse venous sinus may
prove the unifying risk factor for AMS (222).
Freediving (Figure 6B) offers yet another remarkable model
of severe arterial hypoxemia (189, 212). The static apnea
world record currently stands at an impressive 11min 35 s
held by Stéphane Mifsud. However, unlike mountaineers,
apnea results in severe hypercapnia, further compounding
the cerebral hyperemic stimulus (Figure 6B), with freedivers
also having to contend with the additional challenge of
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FIGURE 5 | Challenges for the exercising human brain: applicability of NVU biomarkers. (A) Evolutionary ‘drive-for-size’ with exponential increases in estimated brain
mass observed in fossil hominids. Note the structural complexities and corresponding bioenergetic demands that define the ‘modern’ human brain, highlighting its
limited energy reserves in the form of oxygen (O2), glucose, and adenosine triphosphate (ATP) in the face of extraordinarily high rates of neuronal metabolism. This
renders the human brain exquisitely sensitive to anoxia and ischemia, and thus, it has developed a sophisticated armory of mechanisms that collectively defend O2
homeostasis. Calculations cited and figures modified from (189). (B) Physical exercise poses unique challenges for the human brain with perfusion typically
characterized by preferential redistribution to the phylogenetically ‘older’ regions subserved by the posterior circulation (typical B-mode Doppler images illustrated).
This makes teleological sense given that it is one of the most primitive neuroanatomical regions of the human brain, which has remained highly conserved across
vertebrate evolution housing (almost exclusively) all the major cardiovascular and respiratory control centers essential for the integrated regulation of autonomic
nervous control (190). However, this can come at a cost, with emerging evidence indicating that high flow/pressure and systemic/cerebral formation of free radicals
and oxidative inactivation of nitric oxide [oxidative–nitrosative (OXINOS) stress] contribute to impaired cerebral autoregulation and BBB disruption. The latter is
confirmed through proportional extravasation of brain-specific proteins, including S100B, in the absence of structural tissue damage. BBB permeability can cause
extracellular vasogenic edema resulting in a regional O2 diffusion limitation, with the potential to adversely affect cerebral bioenergetics and cognition. This is relevant
to patients already suffering from impaired cerebral autoregulation/autonomic dysfunction, including older adults, notwithstanding patients diagnosed with diabetes,
hypertension, stroke, and AD (191) (original images by DMB).
elevated hydrostatic pressure when competing ‘at depth’
in select disciplines and complications associated with
pulmonary barotrauma, nitrogen narcosis, decompression
sickness, and high-pressure neurologic syndrome (212).
Competitive freedivers oftentimes experience shallow-
water blackout due to severe cerebral hypoxia and loss of
motor control, clinical signs that are the frustrating cause
for disqualification from competition, notwithstanding
immunochemical evidence for structural NVU damage,
e.g., increased peripheral blood S100B and NSE after a
maximal apnea, with potential long-term neuropsychological
consequences (223, 224).
More recent, direct approaches have taken advantage
of sampling arterial–jugular venous blood and combining
regional measurements of CBF during the course of an apnea
in champion freedivers (213, 214). Despite no detectable O2
gradient across the brain, a truly remarkable observation,
CDO2 subsequent to increased perfusion was well maintained
even at PaO2s as low as 23 mmHg (Figure 6B). Similar to
the aforementioned acute hypoxia study (207), apnea was
associated with a net trans-cerebral outflow of free radicals
and S100B (in the absence of any local gradients in NSE
or MBP) that may reflect minor BBB permeability due to
the combination of hemodynamic (increased intracranial
Frontiers in Neurology | www.frontiersin.org 10 February 2021 | Volume 11 | Article 577312
Janigro et al. Peripheral Biomarkers of Neurovascular Dysfunctions
FIGURE 6 | Beyond barriers: the brain under pressure and NVU blood biomarkers. Extreme examples highlighting how the human brain adapts to the most severe
swings in circulating oxygen, carbon dioxide, and blood volume recorded in the published literature with data obtained from apparently healthy participants. All
examples are unified by a general increase in CBF to ensure preservation of O2 and glucose substrate supply. Note the most hypoxemic (notwithstanding
hypocapnic/hypercapnic) measurements documented in humans (gold, silver, and bronze awarded according to severity of hypoxemia) who regularly operate at the
‘cusp’ of consciousness or indeed beyond. (A) Acute exposure to anoxia (pure nitrogen) resulted in an arterial partial pressure of O2 (PaO2 ) of 16 mmHg (lowest ever
recorded) that resulted in unconsciousness within 16 s (203). The highest recorded femoral arterial puncture performed on an acclimatized mountaineer at 8,400m on
Mt. Everest revealed the second lowest (silver award) PaO2 (and lowest PaCO2) of 19 mmHg (204). Prolonged exposure to the severe hypoxia of terrestrial HA can
result in HACE, a rare albeit deadly syndrome characterized by ataxia resulting in rapid progression to coma. Susceptibility-weighted MRI has revealed hemosiderin
deposits (insoluble iron(III) oxide-hydroxide, reflecting micro-hemorrhages) in nonlethal HACE confined to the genu and splenium of the corpus callosum. In
combination with vasogenic edematous brain swelling previously documented by MRI studies in healthy participants exposed to acute hypoxia (205, 206) and net
trans-cerebral (arterio-jugular venous) outflow of free radicals and S100B (207–209) in the face of impaired dynamic cerebral autoregulation (210) has led to the
suggestion that severe hypoxia results in permeability of the BBB subsequent to molecular (free radical-mediated increase in permeability) and hemodynamic (cerebral
vasodilatation) stress (211). (B) The third lowest PaO2 (and highest PaCO2) recorded in a single freediver during the course of a static breath-hold (apnea) (212, 213).
Note that the level of hypoxemia was so marked there was no observable arterio-jugular venous O2 gradient across the brain (marked cyanosis and ‘black blood’
visible toward the end of apnea). Hypoxic-hypercapnic increase in CBF was sufficient to offset arterial hypoxemia and preserve the cerebral delivery of O2 (CDO2)
(213), though a mild net trans-cerebral outflow in S100B was observed in a follow-up study taken to reflect mild, diffuse BBB disruption (214). (C) Gravitational stress
and reciprocal changes in central blood volume were recently shown to increase blood flow to the posterior region of the brain (VA, vertebral arteries) arguably more
prone to hyperperfusion injury. This was associated with a free radical-mediated reduction in nitric oxide (NO) bioavailability and mild damage of the NVU reflected by
the extravasation of S100B and GFAP (215). Image credits: mountaineering (T*MRI of a 65-year-old woman 7 weeks after having developed HACE at 3,580m,
courtesy of Professor M Knauth, University Hospital Gottingen, Germany); freediver [photographs courtesy of Prof. PN Ainslie and the late Dr. CK Willie, University of
British Columbia, Canada (213) with permission]; Gravity (Novespace’s ZERO-G Airbus A300 credit: Novespace/CNES/DLR/ESA).
pressure) and molecular (increased free radical formation)
stress in the absence of neuronal damage (214). Rather
than consider this simply as a damaging maladaptive
response, vasogenic edematous brain swelling may prove
the adaptive phenotypical response in the hypoxia-tolerant
human brain (211, 225).
GRAVITATIONAL STRESS,
CEREBROVASCULAR REGULATION, AND
BLOOD BIOMARKERS
Alterations in gravitational fluid pressure gradients caused
by the microgravity of orbital spaceflight and hypergravity
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associated with takeoff and landing pose unique physiological
challenges for the astronaut brain. Recent interest has focused
on the complex pathophysiology underlying a constellation of
debilitating neurological, ophthalmological, and neurovestibular
symptoms, known collectively as spaceflight-associated neuro-
ocular syndrome (SANS) (226). At the cellular level, microgravity
has been associated with a loss of cytoskeletal integrity through
dissociation of actin and tubulin bundles (227), and evidence
obtained using animal models suggests that BBB disruption
may occur during the early phases of unloading induced
by suspension or microgravity (228) and during hypergravity
induced by prolonged centrifugation (229, 230). In a recent
study (215), parabolic flight (PF), a ground-based spaceflight
analog, was used as a human model to induce rapidly alternating
shifts in central blood volume during repeated exposures to
microgravity (0 Gz) interspersed with hypergravity (1.8 Gz) (231)
to explore how altered CBF impacts the NVU (232) (Figure 6C).
Blood flow to the posterior cerebral circulation (vertebral
arteries) was selectively elevated during the most marked
gravitational differential from microgravity to hypergravity.
Posterior hyperperfusion was associated with a free radical-
mediated reduction in nitric oxide bioavailability (oxidative–
nitrosative stress) and selective increases in blood S100B and
GFAP that persisted following return to microgravity, whereas
blood biomarkers of neuronal–axonal damage (NSE, NFL, UCH-
L1, and tau) remained stable (215). These findings suggest that
the cumulative effects of repeated gravitational transitions may
promote minor BBB damage due to the combined effects of
hemodynamic-molecular stress. While we appreciate that PF
is an entirely different stimulus dominated by hypergravity,
these findings provide important mechanistic insight to help
understand the neurological risks associated with prolonged
microgravity during spaceflight, given that increased BBB
permeability directly impacts neuronal function, predisposing to
neurological sequelae and brain disease (6).
BLOOD BIOMARKERS OF NVU DAMAGE:
AVAILABLE ANALYTICAL TOOLS,
LIMITATIONS, AND CONTROVERSIES
No single ideal peripheral biomarker exists; rather, a suite of
biomarkers could have a significant diagnostic impact. In recent
years, innovative methods for biomarker detection have been
implemented (Table 2). Reaching high sensitivity has several
advantages, particularly in the context of neurological settings.
Foremost is the ability to detect biomarkers such as NfL, Tau,
or GFAP that are readily present in the CSF and in low
concentrations in the blood. New technology has enabled the
quantification of brain-derived protein biomarkers in blood,
getting one step closer to a minimally invasive diagnosis of
brain damage and neurodegenerative processes. Furthermore,
high-sensitivity methods use microliter quantities of biofluid,
allowing the quantification of several analytes and multiplex
measurement. As an example, we here provide NfL, GFAP,
and tau serum baseline levels as measured in our laboratory
using Simoa (Table 2). We include specific LLOD and LLOQ
TABLE 2A | Available biomarker detection tools.
Novel diagnostic technology Providers
Electrochemiluminescent immunoassay Meso scale discovery
Single-molecule array immunoassay Simoa® (Quanterix)
Immunomagnetic reduction MagQu Co
Proximity extension assay Olink
Immunocapture mass spectrometry Thermo Fisher,
Shimadzu, Agilent, AB
Sciex, Waters
TABLE 2B | Examples of analytical parameters.
NFL GFAP Tau
Control baseline levels 8 pg/ml 54 pg/ml 0.35 pg/ml
Limit of detection (LOD) 0.10 pg/ml 0.22 pg/ml 0.02 pg/ml
Limit of quantification (LOQ) 0.24 pg/ml 0.47 pg/ml 0.05 pg/ml
values relative to our particular experience. Obviously, this
new technology presents limitations. A shortcoming of high-
sensitivity assay resides in the fact that Research Use Only (RUO)
kits are not able to provide, yet, a level of robustness and precision
that one would expect for a clinical in vitro diagnostics (IVD)
use. To date, the impact of analytic interference is not sufficiently
investigated. Therefore, the expectations formulated following
cohort-based studies need confirmations in large preclinical
studies and multicentric clinical trials.
Although the use of blood biomarkers of BBB or neuronal
damage is appealing, a number of clinical stumbling blocks
currently limit full applicability. The usefulness of blood
biomarkers in a given human depends on the availability of
reference values, correcting for age, ethnicity, kidney function,
and body mass index (29). Adequateness of the blood sampling
schedule and availability of baseline controls are crucial for a
reliable biomarker outcome. Sample readiness before and after
pathological events (e.g., inpatient seizure monitoring and head
trauma as in contact sports) provides the optimal framework
to calculate biomarker differential in the same individual and
within a controlled time frame (24, 25). Availability of ad hoc
baseline samples (e.g., specific enrollments for sport events
and military personnel) represents a robust method enabling
personalized medicine.
As examined so far, the appearance of NVU proteins in
blood is reported for neurodegenerative diseases (91, 94), brain
tumors (115, 117), TBI (25, 233), neurologic manifestations
of systemic disease (234), psychiatric diseases, and seizures
(21, 53, 235). Peripheral biomarkers have an excellent NPV to
rule out disease(s) but have a poor positive predictive value
(PPV) to identify a specific pathological condition (27, 28, 46,
53, 236–238). Another concern is the potential contamination
related to extra-CNS sources of protein biomarkers. For example,
S100B could be derived from adipose tissue with levels directly
depending on body mass index (239). A study excluded
the impact of adipose tissue on S100B serum levels (23).
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Elevated serum S100B was reported in patients presenting with
extracranial pathology (240), such as polytrauma and burns (66).
Another important question is whether peripheral biomarkers
have a prognostic value for the development of long-term
brain pathology. Currently, there is no collective agreement
on whether an unhealthy BBB may already exist, and could
be diagnosed, in an otherwise apparently healthy brain (241,
242). However, recent evidence indicates that subjects presenting
early cognitive impairment had preexisting BBB damage. The
platelet-derived growth factor receptor beta (PDGFRβ; Table 1)
(243, 244) shedding from perivascular pericytes was proposed
as a biomarker of BBB integrity anticipating and predicting
neurodegeneration (39, 243). A high-sensitivity method for
detecting pericyte injury quantifying PDGFRβ in CSF was
recently proposed (245). This method could be extended to
study brain pericyte–endothelial damage in neurodegenerative
disorders. Moreover, repetitive head hits during contact sports
[American football (25)] were shown to associate with recurrent
BBB permeability and S100B increases in blood. Players
experiencing recurrent BBB permeability presented higher
serum reactive autoantibodies, with a possible correlation with
cognitive defects (25). The clinical significance of repeated
BBB damage in sports is currently debated, with evidence
pointing to a role in accelerated neurodegeneration (73).
Moreover, total tau in blood was reported as a biomarker of
axonal damage in hockey (24). Tau and amyloid monitoring
in CSF is undergoing validation processes for dementia and
AD (246, 247).
OUTLOOK AND FINAL REMARKS
Using peripheral biomarkers to monitor BBB permeability
could extend to clinical cases where opening of the BBB is
necessary to enhance drug penetration into the brain (13)
or when re-establishment of physiological BBB tightness is
justified to treat brain diseases (248, 249). Emerging evidence
supports a holistic approach to tackle CNS diseases, where
neuronal and cerebrovascular contributors of diseases are
synchronously targeted. An increasing number of BBB-repairing
molecules are currently being tested [for review, see (5, 6)],
targeting NVU cells and neuroinflammation. Importantly, BBB
biomarker and repairing strategies could become important in
the settings of acute or chronic peripheral diseases (infections,
metabolic or inflammatory) where immunity and inflammation
negatively impact BBB permeability and, consequentially,
synaptic transmission (5, 7, 250).
In conclusion, the NVU represents a modern and
integrated entry point for the investigations of brain
functions, and a continuous technological advancement
will be instrumental to improve our ability to link NVU
damage with diagnostics. The field of biomarkers of
NVU damage, or dysfunction, is expanding together
with the use of omic techniques and machine-learning
routines for the discovery of signatures of acute or chronic
disease conditions.
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